Carcinoid tumors are 15 times more common in patients with Crohnʼs disease

West, Natalie E.; Wise, Paul E.; Herline, Alan J.; Muldoon, Roberta L.; Chopp, William V; Schwartz, David L.

doi:10.1002/ibd.20172

Cited by 72 publications

(53 citation statements)

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CAG and inflammatory bowel diseases CAG and inflammatory bowel diseases, already defined as non-oncological causes of CgA elevation, represent for clinicians a diagnostic challenge as they also predispose to NEN development through stimulating proliferation of neuroendocrine cells (Ruszniewski et al 2006, West et al 2007). The possible role of circulating CgA in discriminating patients with CAG and inflammatory bowel diseases who develop gastric (type I) and intestinal NEN, respectively, has been tested by few studies, with non-encouraging results.…”

Section: Diagnostic Role Of Circulating Cga In Particular Clinical Sementioning

confidence: 99%

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Marotta

Zatelli

Sciammarella³

et al. 2018

Endocrine-Related Cancer

125

104

View full text Add to dashboard Cite

Owing to the heterogeneity of neuroendocrine neoplasms (NENs), the availability of reliable circulating markers is critical for improving diagnostics, prognostic stratification, follow-up and definition of treatment strategy. This review is focused on chromogranin A (CgA), a hydrophilic glycoprotein present in large dense core vesicles of neuroendocrine cells. Despite being long identified as the most useful NEN-related circulating marker, clinical application of CgA is controversial. CgA assays still lack standardization, thus hampering not only clinical management but also the comparison between different analyses. In the diagnostic setting, clinical utility of CgA is limited as hampered by (a) the variety of oncological and non-oncological conditions affecting marker levels, which impairs specificity; (b) the fact that 30-50% of NENs show normal CgA, which impairs sensitivity. Regarding the prognostic phase, there is prospective evidence which demonstrates that advanced NENs secreting CgA have poorer outcome, as compared with those showing non-elevated marker levels. Although the identification of cut-offs allowing a proper risk stratification of CgA-secreting patients has not been performed, this represents the most important clinical application of the marker. By contrast, based on prospective studies, the trend of elevated circulating CgA does not represent a valid indicator of morphological evolution and has therefore no utility for the follow-up phase. Ultimately, current knowledge about the role of the marker for the definition of treatment strategy is poor and is limited by the small number of available studies, their prevalent retrospective nature and the absence of control groups of untreated subjects.

show abstract

Section: Diagnostic Role Of Circulating Cga In Particular Clinical Sementioning

confidence: 99%

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Marotta

Zatelli

Sciammarella³

et al. 2018

Endocrine-Related Cancer

125

104

View full text Add to dashboard Cite

show abstract

“…They produce glucagon-like peptides and pancreatic polypeptide, but cause no hormonal syndrome. The few colonic NETs are also small, occur in the cecal region (except if they are associated with ulcerative colitis, Crohn's disease (West et al 2007) and polypous colonic adenomas (Pulitzer et al 2006)) and produce serotonin (Berardi 1972, Rosenberg & Welch 1985, Soga 1998. The NECs of the colon are usually large (O2 cm; Berardi 1972, Soga 1998 and have a high Ki67 index (Burke et al 1991, Crafa et al 2003.…”

Section: Colon and Rectummentioning

confidence: 99%

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

Klöppel¹

2011

Endocrine-Related Cancer

289

219

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are composed of cells with a neuroendocrine phenotype. The old and the new WHO classifications distinguish between well-differentiated and poorly differentiated neoplasms. All well-differentiated neoplasms, regardless of whether they behave benignly or develop metastases, will be called neuroendocrine tumours (NETs), and graded G1 (Ki67 !2%) or G2 (Ki67 2-20%). All poorly differentiated neoplasms will be termed neuroendocrine carcinomas (NECs) and graded G3 (Ki67 O20%). To stratify the GEP-NETs and GEP-NECs regarding their prognosis, they are now further classified according to TNM-stage systems that were recently proposed by the European Neuroendocrine Tumour Society (ENETS) and the AJCC/UICC. In the light of these criteria the pathology and biology of the various NETs and NECs of the gastrointestinal tract (including the oesophagus) and the pancreas are reviewed.

show abstract

“…In the presentation of a case of pediatric age, a primary neuroendocrine tumor of the prostate in conjunction with multiple endocrine neoplasia IIb was described [6]. Furthermore, the incidence of neuroendocrine tumors is increased in individuals with Crohn's disease [7]. Moreover, neuroendocrine differentiation can be observed in 10%-100% of prostatic adenocarcinomas.…”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Tumor of the Prostate with Bone Metastasis

Sivrikaya¹

2014

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetProstatın primer nöroendokrin tümörleri çok nadir ve biyolojik davranışları henüz çok iyi açıklanamamış tümörlerdir. Bu makalede primer prostat nöroendokrin tü-mörü ve kemik metastazı olan bir olgu sunulmaktadır. Altı aydır sık idrara çıkma, işemede zorluk ve mesanesini tam boşaltamama şikayetleri mevcut olan 50 yaşın-da erkek hastaya, transüretral prostat rezeksiyonu yapıldı. Patoloji sonucu az diferansiye nöroendokrin karsinom olarak rapor edildi. Hastanın boyun ağrısı nedeniyle yapılan servikal manyetik rezonans tetkikinde sağ paravertebral yumuşak dokuda bir kitle ve C6 vertebrada patolojik kompresyon kırığı tespit edildi. Hastaya kitlenin eksizyonunu takiben, C6 korpektomi ve homojen kemik grefti konulması operasyonu yapıldı. Paravertebral kitlenin patolojik incelenmesi sonucu az diferansiye nöroendokrin tümor metastazı olduğu tespit edildi. Lezyonun prostatın primer nö-roendokrin tümörünün kemik metastazı olduğu konfirme edilmiş oldu. Anahtar KelimelerProstat; Nöroendokrin; Tümör; Kemik; Metastaz AbstractPrimary neuroendocrine tumors of the prostate are very rare and their biologic behaviour is not yet well described. A case of primary, prostatic, neuroendocrine tumor with bone metastasis is described. A 50-year-old man presented with a 6 months history of frequent urination, difficulty in urination and failure to empty the bladder. Transurethral prostate resection was performed and the pathological examination of the prostate tissue revealed a poorly-differentiated neuroendocrine carcinoma. Meanwhile, cervical magnetic resonance imaging that was planned due to the presence of neck pain revealed a mass lesion in the right paravertebral soft tissue and a pathological compression fracture of the C6 vertebral body. The patient underwent an operation in which C6 corpectomy, placement of homogenous bone graft and obtaining a biopsy specimen were performed. The pathological assessment of the biopsy revealed metastasis of a poorly-differentiated neuroendocrine carcinoma confirming the bone metastasis of the primary neuroendocrine tumor of the prostate.

show abstract

Carcinoid tumors are 15 times more common in patients with Crohnʼs disease

Cited by 72 publications

References 20 publications

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

Primary Neuroendocrine Tumor of the Prostate with Bone Metastasis

Contact Info

Product

Resources

About